



331 Treble Cove Road
North Billerica, MA 01862

800.362.2668
www.lantheus.com

FOR IMMEDIATE RELEASE

CONTACTS:

Investor Relations

John Bakewell
978-436-7073

Media Relations

Meara Murphy
978-671-8508

LANTHEUS HOLDINGS, INC. PRICES ITS INITIAL PUBLIC OFFERING

No. BILLERICA, Mass. (June 24, 2015) – Lantheus Holdings, Inc. (“Lantheus Holdings” or the “Company”), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents and products, announced today the pricing of its initial public offering of 10,833,334 shares of its common stock at a price of \$6.00 per share (the “Offering”). All of the shares in the Offering are being offered by the Company. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,423,243 shares of common stock from the Company. The shares are expected to begin trading on The NASDAQ Global Market on June 25, 2015 under the symbol “LNTH.” The Offering is expected to close on June 30, 2015, subject to customary closing conditions.

Credit Suisse Securities (USA) LLC, Jefferies LLC, RBC Capital Markets, LLC, and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering and Robert W. Baird & Co. Incorporated is acting as co-manager.

The Offering is being made only by means of a prospectus. When available, copies of the prospectus may be obtained from: Credit Suisse Securities (USA) LLC., Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by calling (800) 221-1037, or by emailing newyork.prospectus@credit-suisse.com; and Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by calling (877) 547-6340, or by emailing Prospectus_Department@Jefferies.com.

A registration statement on Form S-1 relating to the Offering has been filed with, and was declared effective by, the Securities and Exchange Commission on June 24, 2015. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. (“LMI”), which is a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. LMI’s key products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechnoLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs.

###